Assignee
REGENERON PHARMA
US·1,347 granted patents·983 pending applications·17,262 citations·filing 1990–2025
Top patents by PatentIndex Score
2,330 records- 0199US11730794B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2020·Granted Aug 22, 2023·8 cites·41 claims
- 0299US11707506B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2021·Granted Jul 25, 2023·5 cites·42 claims
- 0399US11559564B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2022·Granted Jan 24, 2023·5 cites·29 claims
- 0499US11253572B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2021·Granted Feb 22, 2022·11 cites·30 claims
- 0599US11084865B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2020·Granted Aug 10, 2021·14 cites·64 claims
- 0699US10888601B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2019·Granted Jan 12, 2021·14 cites·47 claims
- 0799US10857205B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2018·Granted Dec 8, 2020·14 cites·3 claims
- 0899US10828345B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2018·Granted Nov 10, 2020·19 cites·11 claims
- 0999US10464992B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Nov 5, 2019·60 cites·18 claims
- 1099US10412940B2Mice expressing a limited immunoglobulin light chain repertoireREGENERON PHARMA·Filed 2018·Granted Sep 17, 2019·38 cites·15 claims
- 1199US10406226B2Method of manufacturing VEGF antagonist fusion proteinsREGENERON PHARMA·Filed 2017·Granted Sep 10, 2019·70 cites·4 claims
- 1299US10400025B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Sep 3, 2019·54 cites·15 claims
- 1399US10392430B2Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2017·Granted Aug 27, 2019·37 cites·2 claims
- 1499US9914763B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Mar 13, 2018·56 cites·12 claims
- 1599US9844212B2Human lambda light chain miceREGENERON PHARMA·Filed 2017·Granted Dec 19, 2017·15 cites·30 claims
- 1699US9708386B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2015·Granted Jul 18, 2017·41 cites·5 claims
- 1799US9657102B2Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereofREGENERON PHARMA·Filed 2013·Granted May 23, 2017·125 cites·12 claims
- 1899US9636400B2VEGF specific fusion protein antagonist formulationsREGENERON PHARMA·Filed 2016·Granted May 2, 2017·59 cites·27 claims
- 1999US9580489B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Feb 28, 2017·67 cites·29 claims
- 2099US9546384B2Methods and compositions for the targeted modification of a mouse genomeREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·31 cites·26 claims
- 2199US9340594B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2014·Granted May 17, 2016·73 cites·12 claims
- 2299US9228208B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2014·Granted Jan 5, 2016·79 cites·24 claims
- 2399US9226484B2Human lambda light chain miceREGENERON PHARMA·Filed 2015·Granted Jan 5, 2016·31 cites·7 claims
- 2499US9206263B2Method of making antibodies using a human lambda light chain mouseREGENERON PHARMA·Filed 2015·Granted Dec 8, 2015·33 cites·35 claims
- 2599US9206262B2Method of cloning a lambda light chain variable domain using a human lambda light chain mouseREGENERON PHARMA·Filed 2015·Granted Dec 8, 2015·20 cites·15 claims
- 2699US9163092B2Hybrid light chain miceREGENERON PHARMA·Filed 2015·Granted Oct 20, 2015·36 cites·20 claims
- 2799US9150662B2Hybrid light chain miceREGENERON PHARMA·Filed 2015·Granted Oct 6, 2015·31 cites·20 claims
- 2899US9066502B2Hybrid light chain miceREGENERON PHARMA·Filed 2013·Granted Jun 30, 2015·36 cites·13 claims
- 2999US9029628B2Human lambda light chain miceREGENERON PHARMA·Filed 2013·Granted May 12, 2015·37 cites·21 claims
- 3099US9006511B2Human lambda light chain miceREGENERON PHARMA·Filed 2013·Granted Apr 14, 2015·45 cites·7 claims
- 3199US8802107B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2013·Granted Aug 12, 2014·65 cites·18 claims
- 3299US8735095B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2012·Granted May 27, 2014·103 cites·29 claims
- 3399US8697940B2ADAM6 miceREGENERON PHARMA·Filed 2013·Granted Apr 15, 2014·114 cites·21 claims
- 3499US8343737B2Cell culture compositions capable of producing a VEGF-binding fusion polypeptideREGENERON PHARMA·Filed 2011·Granted Jan 1, 2013·73 cites·12 claims
- 3599US8043617B2Human antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2009·Granted Oct 25, 2011·91 cites·9 claims
- 3699US8029791B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2008·Granted Oct 4, 2011·73 cites·9 claims
- 3799US7807164B2Lyophilized VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2009·Granted Oct 5, 2010·83 cites·9 claims
- 3899US7704500B2Methods of inhibiting ascites formation with modified chimeric VEGF polypeptidesREGENERON PHARMA·Filed 2008·Granted Apr 27, 2010·59 cites·8 claims
- 3999US7608693B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2008·Granted Oct 27, 2009·158 cites·10 claims
- 4099US7582298B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2007·Granted Sep 1, 2009·390 cites·7 claims
- 4199US7435553B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2006·Granted Oct 14, 2008·104 cites·15 claims
- 4299US7396664B2VEGF-binding fusion proteins and nucleic acids encoding the sameREGENERON PHARMA·Filed 2005·Granted Jul 8, 2008·171 cites·11 claims
- 4399US7374757B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2004·Granted May 20, 2008·137 cites·7 claims
- 4499US7374758B2Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereofREGENERON PHARMA·Filed 2004·Granted May 20, 2008·124 cites·3 claims
- 4599US7306799B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 11, 2007·140 cites·11 claims
- 4699US7303747B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 4, 2007·112 cites·6 claims
- 4799US7205148B2Genome mutation by intron insertion into an embryonic stem cell genomeREGENERON PHARMA·Filed 2004·Granted Apr 17, 2007·93 cites·9 claims
- 4899US7105348B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2002·Granted Sep 12, 2006·355 cites·15 claims
- 4999US7087411B2Fusion protein capable of binding VEGFREGENERON PHARMA·Filed 2003·Granted Aug 8, 2006·345 cites·16 claims
- 5099US7070959B1Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2000·Granted Jul 4, 2006·196 cites·15 claims
Showing the top 50 of 2,330 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when REGENERON PHARMA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →